Month: January 2023

– Final cohort of Phase 1 study projected to be complete in H1 2023 – – Phase 2-enabling GLP toxicology studies projected to be complete in H2 2023 – – Clinical update on all pipeline programs to be presented at the 2023 J.P. Morgan Healthcare Conference on January 12 at 10:30 a.m. PT – SOUTH SAN FRANCISCO, Calif., Jan. 05, 2023 (GLOBE NEWSWIRE) — Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that the company remains on track to complete all Phase 2-enabling activities in 2023 for ALG-055009, its thyroid hormone receptor beta (THR-ß) drug candidate for nonalcoholic steatohepatitis (NASH). “Initial Phase 1 clinical data demonstrate that ALG-055009 is favorably differentiated...

NEW YORK, Jan. 05, 2023 (GLOBE NEWSWIRE) — ABM (NYSE: ABM), a leading provider of facility solutions, announced the initiation of an Energy Performance Contracting program for Dooly County School System in Georgia. Creating $3.7 million in projected energy and operating cost savings over a twenty-year period, ABM’s custom solution addresses capital and operational upgrades through ABM’s unique ability to deliver both energy-saving infrastructure solutions and ongoing services such as custodial and maintenance. “Our technical and financial solutions help communities make sure the benefits of their investment are tangible for today’s students,” said Mark Hawkinson, President of ABM Technical Solutions. “We not only improve infrastructure through projects like this for our clients, but we also protect and preserve those investments...

EDGEWOOD, N.Y., Jan. 05, 2023 (GLOBE NEWSWIRE) — CPI Aerostructures, Inc. (CPI Aero® or the Company) (NYSE American: CVU) announced today that an undisclosed aerospace OEM has awarded CPI Aero a $1.8 million contract for complex welded fluid tank assemblies for an unspecified application. Deliveries will begin in 2023 and end in 2024. “This follow-on order demonstrates our customer’s satisfaction with CPI Aero’s performance and continued commitment to excellence. This fluid tank assembly involves complex fusion and resistance welding, and leverages strategic investments CPI Aero has made in welded product capabilities since 2019. These investments were key to the successful transition of this program from development to production, resulting in improved quality and increased throughput,” commented Dorith Hakim, president and chief...

DiaCarta Starts to Receive Samples for Oncuria® Bladder Cancer Test at its CLIA Lab PLEASANTON, Calif. and LOS ANGELES, Jan. 05, 2023 (GLOBE NEWSWIRE) — DiaCarta, Ltd. (“DiaCarta”), a precision molecular diagnostics company, and Nonagen Bioscience Corporation (“Nonagen”), a cancer diagnostics company, today announced the successful completion of the validation study of Oncuria® multiplex bladder cancer immunoassay as a laboratory developed test (“LDT”). DiaCarta also announced that it has begun receiving patient urine samples for testing in its CLIA certified lab in Pleasanton, California. Oncuria is a multiplex protein-based urine test aiming to provide early and accurate detection, therapy choice, and disease monitoring of bladder cancer. Oncuria detects concentrations of 10 proteins associated with bladder cancer in urine samples....

Global registrational trial expected to commence in the second half of 2023 BOSTON and LONDON, Jan. 05, 2023 (GLOBE NEWSWIRE) — Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for OTL-203, a hematopoietic stem cell (HSC) gene therapy being developed for the treatment of the Hurler subtype of mucopolysaccharidosis type I (MPS-IH). The company expects to initiate a global registrational trial evaluating the efficacy and safety of OTL-203 compared to standard of care in the second half of 2023. “Based on data from the proof-of-concept trial, treatment with a single administration of OTL-203 has the potential to address a range of multisystemic manifestations of MPS-IH,” said Leslie Meltzer, Ph.D.,...

MINNEAPOLIS, Jan. 05, 2023 (GLOBE NEWSWIRE) — Tactile Systems Technology, Inc. (“Tactile Medical”) (Nasdaq: TCMD), a medical technology company providing therapies for people with chronic disorders, today announced the appointment of Carmen Volkart to the Company’s Board of Directors (“Board”), effective January 5, 2023. “Carmen joins our Board with more than 40 years of experience in financial and managerial positions, including extensive experience leading medical device companies,” said Bill Burke, Chairman of the Board of Tactile Medical. “We are glad to welcome Carmen to Tactile Medical and look forward to benefiting from her operating expertise and strategic insight.” Since 2018, Carmen Volkart has served as the Chief Financial Officer of NatureWorks LLC, a privately-held advanced materials company and developer of renewably...

SRF114 is designed to preferentially deplete CCR8+ Treg cells within the tumor microenvironment and has demonstrated highly specific CCR8-exclusive binding and reduced tumor growth in pre-clinical studies Initial clinical data anticipated in 2024 CAMBRIDGE, Mass., Jan. 05, 2023 (GLOBE NEWSWIRE) — Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that the first patient has been dosed in its Phase 1/2 clinical study investigating SRF114, a potential best-in-class, fully human, afucosylated anti-CCR8 antibody, as a monotherapy in patients with advanced solid tumors. “Helping patients fight cancer by depleting intra-tumoral regulatory T cells (Tregs) has been a key goal of many immunotherapy strategies for quite...